Devonian Health Group Inc banner

Devonian Health Group Inc
XTSX:GSD

Watchlist Manager
Devonian Health Group Inc Logo
Devonian Health Group Inc
XTSX:GSD
Watchlist
Price: 10.01 CAD Market Closed
Market Cap: CA$27.8m

Devonian Health Group Inc
Other Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Devonian Health Group Inc
Other Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Items CAGR 3Y CAGR 5Y CAGR 10Y
Devonian Health Group Inc
XTSX:GSD
Other Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bausch Health Companies Inc
TSX:BHC
Other Items
-$188m
CAGR 3-Years
-75%
CAGR 5-Years
N/A
CAGR 10-Years
36%
Canopy Growth Corp
TSX:WEED
Other Items
CA$28.3m
CAGR 3-Years
-65%
CAGR 5-Years
N/A
CAGR 10-Years
43%
Cronos Group Inc
TSX:CRON
Other Items
-$50.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Other Items
-$186.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
K
Knight Therapeutics Inc
TSX:GUD
Other Items
-CA$41.5m
CAGR 3-Years
-4%
CAGR 5-Years
N/A
CAGR 10-Years
4%
No Stocks Found

Devonian Health Group Inc
Glance View

Market Cap
27.8m CAD
Industry
Pharmaceuticals

Devonian Health Group, Inc. is a pharmaceutical company, which engages in the development of botanical drugs. The company is headquartered in Pointe-Claire, Quebec. The company went IPO on 2014-09-09. The Company’s flagship product, Thykamine, the pharmaceutical product issued from its SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine have been demonstrated by a considerable number of in vitro and in vivo studies, as well as in a Phase IIa clinical study in patients with Mild-to-Moderate distal Ulcerative Colitis and in a Phase II clinical trial in adult patients with Mild-to-Moderate Atopic Dermatitis. The firm is also involved in the development of cosmeceutical products.

GSD Intrinsic Value
11.62 CAD
Undervaluation 14%
Intrinsic Value
Price CA$10.01

See Also

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett